Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267991 | 0.83 | CYP2A6 (0.60) | CYP2A6MAPTTP53SMN1; SMN2RXFP1 | |
| SCHEMBL20932892 | 0.80 | LTA4H (0.51) | CYP2A6CASP3MAPTTP53SMN1; SMN2 | |
| SCHEMBL13610457 | 0.73 | CYP2A6 (0.39) | CYP2A6MAPTTP53SMN1; SMN2RXFP1 | |
| SCHEMBL13610434 | 0.73 | FFAR2 (0.42) | CYP2A6MAPTTP53SMN1; SMN2RXFP1 | |
| SCHEMBL13610295 | 0.71 | L3MBTL1 (0.50) | CASP3TP53SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL13610476 | 0.70 | CYP2A6 (0.45) | CYP2A6CASP3MAPTSMN1; SMN2IDO1 | |
| SCHEMBL13610311 | 0.70 | RAB9A (0.54) | MAPTTP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL13610299 | 0.70 | LTA4H (0.53) | TDP1L3MBTL1LTA4H | |
| SCHEMBL769511 | 0.69 | IDO1 (0.59) | TP53SMN1; SMN2LTA4HIDO1 | |
| SCHEMBL8587044 | 0.69 | L3MBTL1 (0.43) | CYP2A6CASP3TP53SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742635-B1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-8334316-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334316-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-7622507-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622507-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | TST, CTH, CBS | CYP2A6 2406/4885CASP3 67/4885MAPT 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.